Join the fight to achieve global malaria elimination targets
Donate today and join the fight to achieve global malaria elimination targets.
Together we can make a significant contribution to achieving malaria elimination targets.
Donate today and join the fight to achieve global malaria elimination targets.
Together we can make a significant contribution to achieving malaria elimination targets.
We are investigating the role of mutations in the HIV reverse transcriptase that are highly prevalent in viral isolates from drug-treated individuals on drug resistance and virological failure. This includes silent mutations (that do not code for amino acid changes) selected during drug treatment.
Our studies have led to the identification of N348I in the HIV reverse transcriptase connection domain that is prevalent in drug-treated individuals and leads to dual reverse transcriptase inhibitor class resistance.
Tachedjian G and Sluis-Cremer N. Chapter 13. Role of RNase H activity in NRTI/NNRTI Drug Resistance. pp281 – 303. Edited by Stuart LeGrice and Mattias Gotte. In Human Immunodeficiency virus reverse transcriptase: A bench-to-bedside success. Springer Publishing Company, New York. Published August 2013. ISBN 978-1-4614-7290-2
NHMRC Project Grant 433903. Drug resistance mutations in the connection subdomain of the HIV-1 reverse transcriptase.
NHMRC Project Grant 603704. Silent mutations in the HIV-1 reverse transcriptase selected during antiretroviral therapy.
For any general enquiries relating to this project, please contact:
Head of Life Sciences; Head of Tachedjian Laboratory (Retroviral Biology and Antivirals)